May 20, 2021
Article
The treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.
January 15, 2021
Video
Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
January 15, 2021
Video
Dr Catenacci discusses the DESTINY-Gastric01 study, including personal experience using trastuzumab deruxtecan.
January 15, 2021
Video
Dr Catenacci highlights clinical trials in HER2-positive gastric cancer that may provide insight on differences in mechanism of resistance from one tumor type to another.
January 15, 2021
Video
Daniel Catenacci, MD, discusses treatment options after second-line therapy, highlighting options for patients who are PD-L1 positive.
January 15, 2021
Video
Daniel Catenacci, MD, examines factors that help decide when to switch treatment from first to second line, and when to change mechanism of action in treating gastric carcinoma.